|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Kern MA, Breuhahn K and Schirmacher P:
Molecular pathogenesis of human hepatocellular carcinoma. Adv
Cancer Res. 86:67–112. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lu X, Lu D, Scully M and Kakkar V: ADAM
proteins - therapeutic potential in cancer. Curr Cancer Drug
Targets. 8:720–732. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Seals DF and Courtneidge SA: The ADAMs
family of metalloproteases: multidomain proteins with multiple
functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Klein T and Bischoff R: Active
metalloproteases of the A Disintegrin and Metalloprotease (ADAM)
family: biological function and structure. J Proteome Res.
10:17–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kohga K, Takehara T, Tatsumi T, et al:
Anticancer chemotherapy inhibits MHC class I-related chain a
ectodomain shedding by downregulating ADAM10 expression in
hepatocellular carcinoma. Cancer Res. 69:8050–8057. 2009.
View Article : Google Scholar
|
|
7
|
Lee SB, Schramme A, Doberstein K, et al:
ADAM10 is upregulated in melanoma metastasis compared with primary
melanoma. J Invest Dermatol. 130:763–773. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gaida MM, Haag N, Günther F, et al:
Expression of A disintegrin and metalloprotease 10 in pancreatic
carcinoma. Int J Mol Med. 26:281–288. 2010.PubMed/NCBI
|
|
9
|
Wang YY, Ye ZY, Li L, et al: ADAM 10 is
associated with gastric cancer progression and prognosis of
patients. J Surg Oncol. 103:116–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang CL, Jiang FQ, Xu F and Jiang GX:
ADAM10 overexpression confers resistance to doxorubicin-induced
apoptosis in hepatocellular carcinoma. Tumour Biol. 33:1535–1541.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ko SY, Lin SC, Wong YK, et al: Increase of
disintergin metalloprotease 10 (ADAM10) expression in oral squamous
cell carcinoma. Cancer Lett. 245:33–43. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gavert N, Conacci-Sorrell M, Gast D, et
al: L1, a novel target of beta-catenin signaling, transforms cells
and is expressed at the invasive front of colon cancers. J Cell
Biol. 168:633–642. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Endres K and Fahrenholz F: Upregulation of
the alpha-secretase ADAM10 - risk or reason for hope? FEBS J.
277:1585–1596. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Murai T, Miyazaki Y, Nishinakamura H, et
al: Engagement of CD44 promotes Rac activation and CD44 cleavage
during tumor cell migration. J Biol Chem. 279:4541–4550. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu Q, Liu X, Chen W and Zhang Z:
Inhibiting adenoid cystic carcinoma cells growth and metastasis by
blocking the expression of ADAM 10 using RNA interference. J Transl
Med. 8:1362010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brummelkamp TR, Bernards R and Agami R: A
system for stable expression of short interfering RNAs in mammalian
cells. Science. 296:550–553. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Leng J, Han C, Demetris AJ, Michalopoulos
GK and Wu T: Cyclooxygenase-2 promotes hepatocellular carcinoma
cell growth through Akt activation: Evidence for Akt inhibition in
celecoxib-induced apoptosis. Hepatology. 38:756–768. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kyula JN, Van Schaeybroeck S, Doherty J,
et al: Chemotherapy-induced activation of ADAM-17: a novel
mechanism of drug resistance in colorectal cancer. Clin Cancer Res.
16:3378–3389. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rocks N, Estrella C, Paulissen G, et al:
The metalloproteinase ADAM-12 regulates bronchial epithelial cell
proliferation and apoptosis. Cell Prolif. 41:988–1001. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu K, Liao M, Liu B and Deng Z: ADAM-17
over-expression in gallbladder carcinoma correlates with poor
prognosis of patients. Med Oncol. 28:475–480. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zubel A, Flechtenmacher C, Edler L and
Alonso A: Expression of ADAM9 in CIN3 lesions and squamous cell
carcinomas of the cervix. Gynecol Oncol. 114:332–336. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bai S, Nasser MW, Wang B, et al:
MicroRNA-122 inhibits tumorigenic properties of hepatocellular
carcinoma cells and sensitizes these cells to sorafenib. J Biol
Chem. 284:32015–32027. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yuan S, Lei S and Wu S: ADAM10 is
overexpressed in human hepatocellular carcinoma and contributes to
the proliferation, invasion and migration of HepG2 cells. Oncol
Rep. 30:1715–1722. 2013.
|
|
24
|
Allinson TM, Parkin ET, Turner AJ and
Hooper NM: ADAMs family members as amyloid precursor protein
alpha-secretases. J Neurosci Res. 74:342–352. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jorissen E, Prox J, Bernreuther C, et al:
The disintegrin/metalloproteinase ADAM10 is essential for the
establishment of the brain cortex. J Neurosci. 30:4833–4844. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fan X, Liu Y, Jiang J, et al: miR-20a
promotes proliferation and invasion by targeting APP in human
ovarian cancer cells. Acta Biochim Biophys Sin (Shanghai).
42:318–324. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Venkataramani V, Rossner C, Iffland L, et
al: Histone deacetylase inhibitor valproic acid inhibits cancer
cell proliferation via down-regulation of the alzheimer amyloid
precursor protein. J Biol Chem. 285:10678–10689. 2010. View Article : Google Scholar
|
|
28
|
Zhao H, Zhu J, Cui K, et al:
Bioluminescence imaging reveals inhibition of tumor cell
proliferation by Alzheimer’s amyloid beta protein. Cancer Cell Int.
9:152009.PubMed/NCBI
|
